Valuation: Autolus Therapeutics plc

Market Cap 641M 549M 514M 471M 883M 61.37B 895M 6.07B 2.37B 30.83B 2.41B 2.36B 102B P/E 2026 *
-2.99x
P/E 2027 * -3.53x
Enterprise Value 641M 549M 514M 471M 883M 61.37B 895M 6.07B 2.37B 30.83B 2.41B 2.36B 102B EV / Sales 2026 *
4.28x
EV / Sales 2027 * 3.33x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-2.03%
1 week+12.09%
Current month+61.74%
1 month+64.51%
3 months+46.06%
6 months+44.31%
Current year+21.11%
1 week 2.13
Extreme 2.13
2.58
1 month 1.41
Extreme 1.41
2.58
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Director

310,000 0.1866%
18/3/26 Other

General Counsel

780,818 0.4700%
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%+12.09%+37.71%-25.39% 641M
+0.90%+3.80%+39.43%-1.22% 83.28B
+8.86%+129.20%+453.51%+30.65% 57.92B
-1.69%+23.30%-25.53%-36.93% 57.77B
-1.46%+0.19%-0.81%+29.66% 51.75B
+1.74%+4.43%+11.41%+172.02% 49.35B
+1.13%+3.31%+55.82%-18.22% 32.03B
+0.46%+6.37%+47.71%+96.99% 25.91B
+1.19%+9.17%+3.12%+228.73% 22.74B
-0.30%+4.45%+60.84%+124.17% 16.87B
Average +0.02%+19.68%+68.32%+60.05% 39.83B
Weighted average by Cap. +0.18%+24.95%+82.21%+47.14%

Financials

2026 *2027 *
Net sales 150M 128M 120M 110M 206M 14.33B 209M 1.42B 553M 7.2B 562M 550M 23.81B 192M 165M 154M 141M 265M 18.41B 268M 1.82B 711M 9.25B 723M 707M 30.59B
Net income -219M -187M -175M -161M -301M -20.94B -305M -2.07B -808M -10.52B -822M -804M -34.79B -185M -159M -149M -136M -255M -17.74B -259M -1.76B -685M -8.91B -696M -681M -29.47B
Net Debt - -
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
21/08/26 USD 2.410 -2.03% 2,410,590
20/08/26 USD 2.460 -3.15% 3,254,202
19/08/26 USD 2.540 +10.92% 7,840,758
18/08/26 USD 2.290 +0.44% 3,363,410
17/08/26 USD 2.280 +6.05% 3,036,041
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.410USD
Average target price
8.725USD
Spread / Average Target
+262.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock